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Available online 9 January 2016Myeloid-derived suppressor cells (MDSCs) are potently immunosuppressive innate immune cells that accumu-
late in advanced cancer patients and actively inhibit anti-tumor T lymphocyte responses [1]. Increased numbers
of circulating MDSCs directly correlate with melanoma patient morbidity and reduced anti-tumor immune re-
sponses [2,3]. Previous studies have revealed that monocyte-derived macrophage migration inhibitory factor
(MIF) is necessary for the immune suppressive function ofMDSCs inmousemodels of melanoma [4,5]. To inves-
tigate whetherMIF participates in humanmelanoma-inducedMDSC differentiation and/or suppressive function,
we have established an in vitroMDSC induction model using primary, normal human monocytes co-cultured
with human melanoma cell lines in the presence or absence of the MIF antagonist—4-IPP [4,6–9]. To identify
potential mechanistic effectors, we have performed transcriptome analyses on cultured monocytes and on
melanoma-induced MDSCs obtained from either untreated or 4-IPP-treated A375:monocyte co-cultures. Here,
we present a detailed protocol, which can facilitate easy reproduction of themicroarray results (NCBI GEO acces-
sion number GSE73333) published by Yaddanapudi et al. (2015) in Cancer Immunology Research [10].
© 2015 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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2. Experimental design, materials, and methods
2.1. Monocyte isolation and cell lines
Peripheral bloodwas collected fromhealthy donors. Peripheral blood
mononuclear cells (PBMCs) were isolated from the peripheral blood by
density gradient centrifugation (Ficoll-Hypaque, GE, Piscataway, NJ).
Monocytic CD14+ cells were isolated from PBMCs using anti-CD14
magnetic microbeads and the autoMACS Pro Separator (Miltenyi Biotec,
Auburn, CA), per manufacturer's instructions. Purity of isolated cell
populations was N90%, as evaluated by ﬂow cytometry. Melanoma cell
line [A375] (ATCC® CRL-1619™) was purchased from ATCC (Manassas,
VA) and maintained in DMEM containing 10% (v/v) FBS. We do not
culture this cell line for longer than 6–8 weeks and all cell-stocks came
from thawed vials that were frozen at passage two after receiving from-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Tandem Repeat (STR) proﬁling.2.2. In vitro generation of human MDSC and MIF-inhibitor treatment
We established an in vitro model of melanoma cell-line-induced
MDSCs that faithfully recapitulates patient-derived CD14+HLADR−/low
monocytic MDSC phenotype and function [9,10]. CD14+ cells
(1 × 106 cells/well), isolated from PBMCs obtained fromhealthy donors,
were co-culturedwith A375 tumor cells (5× 105 cells/well) in complete
IMDM (supplemented with 10% human AB serum [Sigma-Aldrich,
St. Louis, MO], L-glutamine [2 mM], and penicillin/streptomycin) per
well in a 6-well plate (BD Falcon). Tumor/monocyte co-cultures were
treated twice with the small molecule inhibitor of MIF, 4-IPP (100 μM
on day 0 and 50 μM on day 2), or 0.1% DMSO (vehicle control). A375
co-cultured monocytes (both vehicle-treated and 4-IPP-treated) and
control monocytes cultured without tumor cells (cultured monocytes)
were gently harvested after 64–68 h of culture and CD11b+ cells
(A375-MDSCs) were puriﬁed with anti-CD11b+ microbeads and
autoMACS separator (Miltenyi Biotec) (Fig. 1). Purity of isolated cell
populations was N90% as evaluated by ﬂow cytometry. We refer to
the CD11b+ cells isolated from the A375 monocyte co-cultures as
A375-MDSCs although we are cognizant of the fact that these cells
represent a heterogenous population of cells [2]. The percentage of
CD14+CD11b+CD33+HLADR−/low cells are substantially increased in
A375-monocyte co-cultures in comparison to that ofmonocytes cultured
in the absence of melanoma cells—an expression signature that closelyFig. 1. Schematic representation of the experimental design for themicroarray analysis. (A) Nor
(MDSC induction). CD11b+ A375-MDSCs were isolated from the co-cultures by anti-CD11b
microarray analysis was subsequently isolated from the puriﬁed A375-MDSCs; (B) 4-IPP (50 μ
which was followed by the isolation of RNA from the puriﬁed 4-IPP-treated MDSCs; and (
(cultured monocytes control).corresponds tomonocyticMDSCs isolated from late stagemelanoma pa-
tients [10–12]. Furthermore, in contrast to tumor cell-free cultured
monocytes, A375-MDSCs exhibit potent suppressive activity against
autologous T cell proliferation and IFN-γ production [9,10].2.3. Microarray Analysis
Gene expression proﬁles of vehicle-treated A375-MDSCs or 4-IPP-
treated A375-MDSCs (A375-MDSC+4-IPP) were compared to that
obtained using monocytes cultured without tumor cells (Fig. 1). Total
RNA from cultured monocytes, vehicle-treated, and 4-IPP-treated
A375-MDSCs (n = 3) were isolated post-68 h in vitro culture and ana-
lyzed over a microarray. For RNA extraction, cells were lysed in buffer
RLT (Qiagen, Valencia, CA), homogenized, and puriﬁed using RNeasy
mini kit (Qiagen) following manufacturer's instructions. Integrity of
RNA was checked using a Bioanalyzer 2100 (Agilent Technologies,
Santa Clara, CA). Biotinylated cRNA was prepared from 100 ng of total
RNA according to the standard protocol for Affymetrix 3′ IVT Express
Plus Reagent kit. Following fragmentation, cRNA was hybridized for
16 h at 45 °C to Affymetrix Primeview Human arrays according to the
GeneChip 3′ Array Hybridization User Manual from Affymetrix. The
arrays were processed following the manufacturer recommended
wash and stain protocol on an Affymetrix FS-450 ﬂuidics station and
scanned on an Affymetrix GeneChip scanner. The resulting .cel ﬁles
were imported into Partek Genomics Suite 6.6 and transcriptswere nor-
malized and summarized using RMA as normalization and background
correctionmethod. Contrasts in a 1-wayANOVAwere set up to comparemal donor CD14+monocyteswere co-culturedwith human A375melanoma cells for 68 h
+ microbead labeling and magnetic column separation (MDSC isolation). RNA for the
M) was added during the A375:monocyte MDSC induction phase (A375-MDSC + 4-IPP),
C) RNA was isolated from monocytes that were cultured for 68 h without tumor cells
242 S. Waigel et al. / Genomics Data 7 (2016) 240–242the treatments of interest. Step-up False Discovery Rate was chosen as
multiple test correction for the resulting p-values. The microarray
datasets discussed in current study have been deposited in NCBI's
Gene Expression Omnibus (GEO; www.ncbi.nlm.nih.gov/geo) and are
accessible through GEO Series accession number GSE73333.
3. Conclusions
A microarray analysis of normal monocytes, vehicle-treated-A375-
MDSCs, and 4-IPP-treated A375-MDSCs was performed to identify
downstream MIF effectors that could be responsible for MIF-dependent
phenotypic and functional contributions to human MDSCs. Melanoma
cell line-induced MDSC transcriptome reveals a unique gene expression
proﬁle that is largely reversed to normal monocyte levels by MIF inhibi-
tion. Inﬂammatory cytokines, chemokines/chemokine receptors, matrix
metalloproteases, angiogenic growth factors, and arachidonic acid/
prostaglandin-generating enzymes are all differentially expressed in
A375-MDSCs and restored to “normal” levels by MIF inhibition. These
results are discussed in detail in the article published by Yaddanapudi
et al. (2015) in Cancer Immunology Research [10].
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